These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 25104068)
1. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme. Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068 [TBL] [Abstract][Full Text] [Related]
2. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Laprie A; Catalaa I; Cassol E; McKnight TR; Berchery D; Marre D; Bachaud JM; Berry I; Moyal EC Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):773-81. PubMed ID: 18262090 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898 [TBL] [Abstract][Full Text] [Related]
4. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746 [TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Park I; Tamai G; Lee MC; Chuang CF; Chang SM; Berger MS; Nelson SJ; Pirzkall A Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):381-9. PubMed ID: 17513061 [TBL] [Abstract][Full Text] [Related]
6. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908 [TBL] [Abstract][Full Text] [Related]
7. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors]. Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499 [TBL] [Abstract][Full Text] [Related]
8. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes. Parra NA; Maudsley AA; Gupta RK; Ishkanian F; Huang K; Walker GR; Padgett K; Roy B; Panoff J; Markoe A; Stoyanova R Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):376-84. PubMed ID: 25066215 [TBL] [Abstract][Full Text] [Related]
9. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135 [TBL] [Abstract][Full Text] [Related]
10. Association of Radiomics and Metabolic Tumor Volumes in Radiation Treatment of Glioblastoma Multiforme. Lopez CJ; Nagornaya N; Parra NA; Kwon D; Ishkanian F; Markoe AM; Maudsley A; Stoyanova R Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):586-595. PubMed ID: 28011044 [TBL] [Abstract][Full Text] [Related]
11. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. Oh J; Henry RG; Pirzkall A; Lu Y; Li X; Catalaa I; Chang S; Dillon WP; Nelson SJ J Magn Reson Imaging; 2004 May; 19(5):546-54. PubMed ID: 15112303 [TBL] [Abstract][Full Text] [Related]
12. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868 [TBL] [Abstract][Full Text] [Related]
13. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634 [TBL] [Abstract][Full Text] [Related]
14. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Nelson SJ; Kadambi AK; Park I; Li Y; Crane J; Olson M; Molinaro A; Roy R; Butowski N; Cha S; Chang S Neuro Oncol; 2017 Mar; 19(3):430-439. PubMed ID: 27576874 [TBL] [Abstract][Full Text] [Related]
15. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. Chan AA; Lau A; Pirzkall A; Chang SM; Verhey LJ; Larson D; McDermott MW; Dillon WP; Nelson SJ J Neurosurg; 2004 Sep; 101(3):467-75. PubMed ID: 15352605 [TBL] [Abstract][Full Text] [Related]
16. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. Smith EA; Carlos RC; Junck LR; Tsien CI; Elias A; Sundgren PC AJR Am J Roentgenol; 2009 Feb; 192(2):W45-52. PubMed ID: 19155380 [TBL] [Abstract][Full Text] [Related]
17. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Zeng QS; Li CF; Liu H; Zhen JH; Feng DC Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287 [TBL] [Abstract][Full Text] [Related]
18. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374 [TBL] [Abstract][Full Text] [Related]
19. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. Weybright P; Sundgren PC; Maly P; Hassan DG; Nan B; Rohrer S; Junck L AJR Am J Roentgenol; 2005 Dec; 185(6):1471-6. PubMed ID: 16304000 [TBL] [Abstract][Full Text] [Related]
20. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]